Inventor · disambiguated record
Eric Smith
Also filed as: SMITH ERIC · SMITH ERIC L · SMITH ERIC LEIGHTON
97 granted patents·50 pending applications·1,893 citations·filing 1980–2025
99Inventor score
Files withREGENERON PHARMA95MEMORIAL SLOAN KETTERING CANCER CENTER22AOB PRODUCTS COMPANY7SMITH ERIC L5JUNO THERAPEUTICS INC4
Top patents by PatentIndex Score
147 records- 0199US9657102B2Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereofREGENERON PHARMA·Filed 2013·Granted May 23, 2017·125 cites·12 claims
- 0299US8043617B2Human antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2009·Granted Oct 25, 2011·91 cites·9 claims
- 0399US7582298B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2007·Granted Sep 1, 2009·390 cites·7 claims
- 0497US11000549B2Methods of using chimeric antigen receptors targeting B-cell maturation antigen and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted May 11, 2021·6 cites·20 claims
- 0597US10906956B2Methods of treatments using chimeric antigen receptors targeting G-protein coupled receptorMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Feb 2, 2021·7 cites·20 claims
- 0697US10821135B2Nucleic acid molecules encoding chimeric antigen receptors targeting B-cell maturation antigen and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2020·Granted Nov 3, 2020·7 cites·30 claims
- 0797US10772972B2Anti-STEAP2 antibody drug conjugates, and compositions and uses thereofREGENERON PHARMA·Filed 2017·Granted Sep 15, 2020·44 cites·41 claims
- 0897US10179819B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2016·Granted Jan 15, 2019·25 cites·12 claims
- 0997US9359437B2Antibodies comprising chimeric constant domainsREGENERON PHARMA·Filed 2014·Granted Jun 7, 2016·91 cites·21 claims
- 1097US8586713B2Readily isolated bispecific antibodies with native immunoglobulin formatDAVIS SAMUEL·Filed 2010·Granted Nov 19, 2013·422 cites·8 claims
- 1197US7534868B1Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2009·Granted May 19, 2009·38 cites·6 claims
- 1297US7488806B2Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2008·Granted Feb 10, 2009·41 cites·8 claims
- 1396US12180272B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Dec 31, 2024·2 cites·11 claims
- 1496US11708407B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2022·Granted Jul 25, 2023·2 cites·26 claims
- 1596US10918665B2Chimeric antigen receptors targeting B-cell maturation antigen and uses thereofMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Feb 16, 2021·16 cites·57 claims
- 1696US10738130B2Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·50 cites·49 claims
- 1796US10556952B2Heavy chain constant regions with reduced binding to Fc gamma receptorsREGENERON PHARMA·Filed 2016·Granted Feb 11, 2020·12 cites·24 claims
- 1896US9884916B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2016·Granted Feb 6, 2018·13 cites·7 claims
- 1995US11725059B2Antibodies targeting B-cell maturation antigen and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2021·Granted Aug 15, 2023·3 cites·40 claims
- 2095US11725034B2IL2 agonists and methods of use thereofREGENERON PHARMA·Filed 2022·Granted Aug 15, 2023·4 cites·30 claims
- 2195US11518807B2Heavy chain constant regions with reduced binding to Fc gamma receptorsREGENERON PHARMA·Filed 2019·Granted Dec 6, 2022·8 cites·40 claims
- 2295US11485793B2Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·4 cites·44 claims
- 2395US11155633B2Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereofREGENERON PHARMA·Filed 2018·Granted Oct 26, 2021·9 cites·24 claims
- 2495US10988537B2Antibodies comprising chimeric constant domainsREGENERON PHARMA·Filed 2018·Granted Apr 27, 2021·10 cites·20 claims
- 2595US7919593B2Human antibodies to human delta like ligand 4REGENERON PHARMA·Filed 2007·Granted Apr 5, 2011·25 cites·22 claims
- 2694US12065508B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2022·Granted Aug 20, 2024·3 cites·25 claims
- 2794US11952430B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2022·Granted Apr 9, 2024·3 cites·24 claims
- 2894US11633501B2Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Apr 25, 2023·3 cites·14 claims
- 2994US11548947B2Bispecific anti-PSMA X anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jan 10, 2023·10 cites·17 claims
- 3094US11384153B2Bispecific anti-BCMA x anti-CD3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 12, 2022·16 cites·24 claims
- 3194US10562972B2Antibodies targeting B-cell maturation antigen and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Feb 18, 2020·9 cites·67 claims
- 3294US8192741B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2011·Granted Jun 5, 2012·22 cites·10 claims
- 3394US8048418B2Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonistsREGENERON PHARMA·Filed 2009·Granted Nov 1, 2011·34 cites·6 claims
- 3493US12077603B2Multispecific antigen-binding molecules for cell targeting and uses thereofREGENERON PHARMA·Filed 2020·Granted Sep 3, 2024·3 cites·28 claims
- 3593US11453721B2Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Sep 27, 2022·10 cites·30 claims
- 3693US10947314B2Antibodies targeting b-cell maturation antigen and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2019·Granted Mar 16, 2021·5 cites·30 claims
- 3793US10941208B2Anti-MUC16 antibodiesREGENERON PHARMA·Filed 2017·Granted Mar 9, 2021·6 cites·2 claims
- 3893US10550193B2Methods and antibody compositions for tumor treatmentREGENERON PHARMA·Filed 2015·Granted Feb 4, 2020·8 cites·32 claims
- 3993US8568721B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyRADIN ALLEN·Filed 2012·Granted Oct 29, 2013·18 cites·9 claims
- 4093US2025206829A1High affinity antibodies to human il-6 receptorREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4192US12391753B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Granted Aug 19, 2025·0 cites·22 claims
- 4292US11905332B2Antigen-binding molecules that bind CD38 and/or CD28, and uses thereofREGENERON PHARMA·Filed 2021·Granted Feb 20, 2024·3 cites·43 claims
- 4392US8183014B2High affinity antibodies to human IL-6 receptorSTEVENS SEAN·Filed 2011·Granted May 22, 2012·11 cites·19 claims
- 4491US12215148B2Antigen binding molecule formatsREGENERON PHARMA·Filed 2020·Granted Feb 4, 2025·2 cites·25 claims
- 4591US11396544B2Bispecific anti-CD28 × anti-CD22 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 26, 2022·8 cites·10 claims
- 4691US11066475B2Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotidesJUNO THERAPEUTICS INC·Filed 2018·Granted Jul 20, 2021·10 cites·23 claims
- 4791US10590196B2Antibodies targeting G-protein coupled receptor and methods of useMEMORIAL SLOAN KETTERING CANCER CENTER·Filed 2017·Granted Mar 17, 2020·10 cites·46 claims
- 4891US9308256B2Method of treating rheumatoid arthritis with an anti-IL-6R antibodyREGENERON PHARMA·Filed 2013·Granted Apr 12, 2016·11 cites·14 claims
- 4991US8080248B2Method of treating rheumatoid arthritis with an IL-6R antibodyRADIN ALLEN·Filed 2010·Granted Dec 20, 2011·15 cites·11 claims
- 5091US2025333492A1Antigen binding molecule formatsREGENERON PHARMA·Filed 2024·Application pending·0 cites
Showing the top 50 of 147 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →